Personalization of cancer treatment using predictive simulation.

Area of Science:

• Oncology
• Computational Biology
• Genomics

Background:

• Cancer treatment is shifting from a one-size-fits-all approach to personalized medicine.
• Next-generation sequencing (NGS) is increasingly used to identify cancer cell mutations and copy number aberrations.
• Current personalized therapies often target single oncogenes, which may be insufficient for complex cancers with multiple aberrations.

Purpose of the Study:

• To develop a novel predictive simulation approach for creating personalized cancer therapeutics.
• To address the challenge of interpreting genomic data into actionable clinical insights for cancer treatment.
• To identify effective drug combinations that target multiple pathways and overcome single-therapy resistance.

Main Methods:

• A predictive simulation approach was used to create patient-specific cancer cell avatars based on genomic data (point mutations and copy number aberrations).
• Avatars of high-risk multiple myeloma patients were functionally screened with various targeted drugs, both individually and in combination.
• Drug repurposing of FDA-approved or clinically studied agents with established safety and pharmacokinetic data was employed for rapid clinical translation.

Main Results:

• The predictive platform successfully identified personalized drug regimens for four high-risk multiple myeloma patients.
• The predicted drug regimens demonstrated efficacy in ex vivo analyses using patient-derived cells.
• The approach enables the rational design of personalized treatments targeting multiple pathways to combat therapy resistance.

Conclusions:

• The study validates a novel methodology for personalized therapeutics using big data and predictive simulation.
• This approach facilitates the interpretation of genomic signatures into practical, personalized cancer treatment strategies.
• The findings support the use of predictive simulation for developing effective, multi-targeted cancer therapies.